Join
Live feed
·
PRReleasevia Quantisnow
Trevi Therapeutics Inc. logo

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
TRVI· Trevi Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRVI (Trevi Therapeutics Inc.) and more on Quantisnow.